×
About 33,161 results

ALLMedicine™ Hodgkin Lymphoma Center

Research & Reviews  15,335 results

18F-FDG positron emission tomography scanning in systemic sclerosis-associated intersti...
https://doi.org/10.1186/s13075-021-02460-8 10.1007/s12016-010-8198-y 10.1007/s12016-009-8194-2 10.1136/ard.2006.066068 10.1186/s13075-019-1867-1 10.1164/rccm.2106012 10.1002/art.39166 10.1093/rheumatology/kev016 10.2147/OARRR.S226695 10.1002/art.22204 10.1056/NEJMoa055120 10.1002/art.40114 10.1136/annrheumdis-2016-209909 10.5301/jsrd.5000205 10.1186/s13075-015-0872-2 10.1378/chest.13-2626 10.1371/journal.pone.0181692 10.1097/BOR.0000000000000656 10.1136/thoraxjnl-2018-211779 10.1056/NEJMoa1903076 10.2967/jnumed.116.174946 10.1016/j.ejrad.2016.10.001 10.1007/s00259-013-2514-8 10.1007/s12350-016-0649-2 10.4103/0972-3919.178335 10.4103/0972-3919.164018 10.1164/rccm.201308-1483ST 10.1088/0031-9155/60/18/7387 10.2967/jnumed.116.184796 10.4329/wjr.v6.i10.779 10.1002/art.38098 10.1164/rccm.200706-877OC 10.1093/rheumatology/ken271 10.2967/jnumed.114.147421 10.1164/rccm.201504-0780OC 10.1164/rccm.201508-1699ED 10.1016/j.ejrad.2016.09.014 10.1186/s12931-017-0556-3 10.2967/jnumed.115.163360 10.1097/MNM.0000000000000083 10.1007/s00259-011-1986-7 10.1007/s00259-009-1069-1 10.1136/annrheumdis-2018-21337652 10.1016/S1095-0397(99)00016-3
Arthritis Research & Therapy; Ledoult E, Morelle M et. al.

Mar 6th, 2021 - Interstitial lung disease is a common complication of systemic sclerosis (SSc-ILD), and it remains difficult to accurately predict its course. Progressing ILD could be more metabolically active, suggesting that the 18F-FDG tracer could be a tool i...

Efficacy of decitabine plus anti-PD-1 camrelizumab in patients with Hodgkin lymphoma wh...
https://doi.org/10.1158/1078-0432.CCR-21-0133
Clinical Cancer Research : an Official Journal of the Ame... Wang C, Liu Y et. al.

Mar 6th, 2021 - Programmed death-1 (PD-1) blockade monotherapy is effective in relapsed/refractory classical Hodgkin lymphoma (cHL), but a subset of patients is recalcitrant to PD-1 inhibitors and only a minority of patients achieves durable remission. Effective ...

Late toxicities in non-Hodgkin lymphoma: extended follow-up matters.
https://doi.org/10.1016/S2352-3026(21)00058-2
The Lancet. Haematology; Thanarajasingam G, Smedby KE et. al.

Mar 5th, 2021 - Late toxicities in non-Hodgkin lymphoma: extended follow-up matters.|2021|Thanarajasingam G,Smedby KE,LaCasce A,|

COVID-19 Vaccine-Related Local FDG Uptake.
https://doi.org/10.1097/RLU.0000000000003634
Clinical Nuclear Medicine; Doss M, Nakhoda SK et. al.

Mar 4th, 2021 - We present a case of increased FDG uptake in the lymph nodes after COVID-19 vaccine administration. Restaging PET/CT scan of a 70-year-old woman with a history of multiple relapsed Hodgkin lymphoma showed muscle activity in the left upper arm late...

see more →

Guidelines  111 results

Adult Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version
https://www.cancer.gov/types/lymphoma/hp/adult-hodgkin-treatment-pdq?cid=eb_govdel
National Cancer Institute

Jan 14th, 2021 - More than 75% of all newly diagnosed patients with adult HL can be cured with combination chemotherapy and/or radiation therapy.[2] Over the last five decades, U.S. national mortality has fallen more rapidly for adult HL than for any other maligna...

Lisocabtagene maraleucel CAR T shows durable response in large B-cell NHL
https://www.healio.com/news/hematology-oncology/20200709/lisocabtagene-maraleucel-car-t-shows-durable-response-in-large-bcell-nhl

Jul 8th, 2020 - In updated results of the pilot study, presented during the ASCO2020 Virtual Scientific Program, researchers showed that lisocabtagene maraleucel induced durable response as a second-line treatment in large B-cell non-Hodgkin lymphoma.

Pembrolizumab prolonged PFS vs. brentuximab vedotin in r/r Hodgkin lymphoma
https://www.mdedge.com/hematology-oncology/article/223065/hodgkin-lymphoma/pembrolizumab-prolonged-pfs-vs-brentuximab

May 31st, 2020 - Pembrolizumab treatment significantly improved progression-free survival versus brentuximab vedotin in a recent randomized, phase 3 trial including patients with relapsed or refractory classical Hodgkin lymphoma, an investigator has reported.

CAR-T continues to show durable responses in indolent non-Hodgkin lymphoma
https://www.healio.com/hematology-oncology/lymphoma/news/online/{b5b2d115-7000-4df9-8743-26711c3bbde1}/car-t-continues-to-show-durable-responses-in-indolent-non-hodgkin-lymphoma

May 30th, 2020 - Axicabtagene ciloleucel induced a 93% response rate among patients with relapsed or refractory indolent non-Hodgkin lymphoma, according to interim results of the phase 2 ZUMA-5 trial presented during the ASCO20 Virtual Scientific Program.

CAR T-Cell Therapy Impresses in Indolent NHL
https://www.medpagetoday.com/meetingcoverage/asco/86783

May 30th, 2020 - Almost 100% of patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL) responded to treatment with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel, Yescarta), data from an ongoing study showed.

see more →

Drugs  81 results see all →

Clinicaltrials.gov  16,537 results

18F-FDG positron emission tomography scanning in systemic sclerosis-associated intersti...
https://doi.org/10.1186/s13075-021-02460-8 10.1007/s12016-010-8198-y 10.1007/s12016-009-8194-2 10.1136/ard.2006.066068 10.1186/s13075-019-1867-1 10.1164/rccm.2106012 10.1002/art.39166 10.1093/rheumatology/kev016 10.2147/OARRR.S226695 10.1002/art.22204 10.1056/NEJMoa055120 10.1002/art.40114 10.1136/annrheumdis-2016-209909 10.5301/jsrd.5000205 10.1186/s13075-015-0872-2 10.1378/chest.13-2626 10.1371/journal.pone.0181692 10.1097/BOR.0000000000000656 10.1136/thoraxjnl-2018-211779 10.1056/NEJMoa1903076 10.2967/jnumed.116.174946 10.1016/j.ejrad.2016.10.001 10.1007/s00259-013-2514-8 10.1007/s12350-016-0649-2 10.4103/0972-3919.178335 10.4103/0972-3919.164018 10.1164/rccm.201308-1483ST 10.1088/0031-9155/60/18/7387 10.2967/jnumed.116.184796 10.4329/wjr.v6.i10.779 10.1002/art.38098 10.1164/rccm.200706-877OC 10.1093/rheumatology/ken271 10.2967/jnumed.114.147421 10.1164/rccm.201504-0780OC 10.1164/rccm.201508-1699ED 10.1016/j.ejrad.2016.09.014 10.1186/s12931-017-0556-3 10.2967/jnumed.115.163360 10.1097/MNM.0000000000000083 10.1007/s00259-011-1986-7 10.1007/s00259-009-1069-1 10.1136/annrheumdis-2018-21337652 10.1016/S1095-0397(99)00016-3
Arthritis Research & Therapy; Ledoult E, Morelle M et. al.

Mar 6th, 2021 - Interstitial lung disease is a common complication of systemic sclerosis (SSc-ILD), and it remains difficult to accurately predict its course. Progressing ILD could be more metabolically active, suggesting that the 18F-FDG tracer could be a tool i...

Efficacy of decitabine plus anti-PD-1 camrelizumab in patients with Hodgkin lymphoma wh...
https://doi.org/10.1158/1078-0432.CCR-21-0133
Clinical Cancer Research : an Official Journal of the Ame... Wang C, Liu Y et. al.

Mar 6th, 2021 - Programmed death-1 (PD-1) blockade monotherapy is effective in relapsed/refractory classical Hodgkin lymphoma (cHL), but a subset of patients is recalcitrant to PD-1 inhibitors and only a minority of patients achieves durable remission. Effective ...

Late toxicities in non-Hodgkin lymphoma: extended follow-up matters.
https://doi.org/10.1016/S2352-3026(21)00058-2
The Lancet. Haematology; Thanarajasingam G, Smedby KE et. al.

Mar 5th, 2021 - Late toxicities in non-Hodgkin lymphoma: extended follow-up matters.|2021|Thanarajasingam G,Smedby KE,LaCasce A,|

COVID-19 Vaccine-Related Local FDG Uptake.
https://doi.org/10.1097/RLU.0000000000003634
Clinical Nuclear Medicine; Doss M, Nakhoda SK et. al.

Mar 4th, 2021 - We present a case of increased FDG uptake in the lymph nodes after COVID-19 vaccine administration. Restaging PET/CT scan of a 70-year-old woman with a history of multiple relapsed Hodgkin lymphoma showed muscle activity in the left upper arm late...

see more →

News  1,093 results

Remission of Hodgkin Lymphoma After COVID-19
https://www.medscape.com/viewarticle/945856

Feb 15th, 2021 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Patients with cancer are considered at risk for COVID-19, but in some cases, could the infection be a good thing? A case report of a patient with ...

Anti-CD20 Therapy for Lymphoma Tied to Worse COVID-19 Outcomes
https://www.medscape.com/viewarticle/945496

Feb 8th, 2021 - NEW YORK (Reuters Health) - Lymphoma patients treated with B-cell-depleting anti-CD20 monoclonal antibodies, such as rituximab or obinutuzumab, may have worse outcomes from COVID-19 infection, according to a study from France. "More than 20 years ...

Fast Five Quiz: Waldenström Macroglobulinemia Workup
https://reference.medscape.com/viewarticle/944100

Jan 31st, 2021 - Waldenström macroglobulinemia (WM) is an indolent subtype of non-Hodgkin lymphoma (NHL) that affects small lymphocytes. WM is rare, accounting for approximately 2% of hematologic malignancies with 1500 cases diagnosed per year in the United States...

Adult Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version
https://www.cancer.gov/types/lymphoma/hp/adult-hodgkin-treatment-pdq?cid=eb_govdel
National Cancer Institute

Jan 14th, 2021 - More than 75% of all newly diagnosed patients with adult HL can be cured with combination chemotherapy and/or radiation therapy.[2] Over the last five decades, U.S. national mortality has fallen more rapidly for adult HL than for any other maligna...

First Data for CAR T-cell Therapy in Follicular Lymphoma: ZUMA-5
https://www.medscape.com/viewarticle/942494

Dec 10th, 2020 - For the first time, a chimeric antigen receptor (CAR) therapy has yielded a high response rate among patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL), including patients with follicular lymphoma (FL) and marginal zone lymphom...

see more →

Patient Education  4 results see all →